Literature DB >> 29183623

Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.

Yu-Xin Xu1, Valeska Redon2, Haojie Yu3, William Querbes4, James Pirruccello1, Abigail Liebow4, Amy Deik5, Kevin Trindade2, Xiao Wang6, Kiran Musunuru6, Clary B Clish5, Chad Cowan7, Kevin Fizgerald4, Daniel Rader2, Sekar Kathiresan8.   

Abstract

BACKGROUND AND AIMS: Angiopoietin-like 3 (ANGPTL3) has emerged as a key regulator of lipoprotein metabolism in humans. Homozygous loss of ANGPTL3 function causes familial combined hypolipidemia characterized by low plasma levels of triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). While known effects of ANGPTL3 in inhibiting lipoprotein lipase and endothelial lipase contribute to the low TG and HDL-C, respectively, the basis of low LDL-C remains unclear. Our aim was to explore the role of ANGPTL3 in modulating plasma LDL-C.
METHODS: We performed RNAi-mediated gene silencing of ANGPTL3 in five mouse models and in human hepatoma cells. We validated results by deleting ANGPTL3 gene using the CRISPR/Cas9 genome editing system.
RESULTS: RNAi-mediated Angptl3 silencing in mouse livers resulted in very low TG, HDL-C and LDL-C, a pattern similar to the human phenotype. The effect was observed in wild-type and obese mice, while in hCETP/apolipoprotein (Apo) B-100 double transgenic mice, the silencing decreased LDL-C and TG, but not HDL-C. In a humanized mouse model (Apobec1-/- carrying human ApoB-100 transgene) deficient in the LDL receptor (LDLR), Angptl3 silencing had minimum effect on LDL-C, suggesting the effect being linked to LDLR. This observation is supported by an additive effect on LDL-C between ANGPTL3 and PCSK9 siRNAs. ANGPTL3 gene deletion induced cellular long-chain TG and ApoB-100 accumulation with elevated LDLR and LDLR-related protein (LRP) 1 expression. Consistent with this, ANGPTL3 deficiency by gene deletion or silencing reduced nascent ApoB-100 secretion and increased LDL/VLDL uptake.
CONCLUSIONS: Reduced secretion and increased uptake of ApoB-containing lipoproteins may contribute to the low LDL-C observed in mice and humans with genetic ANGPTL3 deficiency.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ANGPTL3; Angiopoietin-like protein 3; Cholesterol; HDL; High-density lipoprotein; LDL; LDL receptor; LDLR; Lipoprotein; Low-density lipoprotein; Triglycerides

Mesh:

Substances:

Year:  2017        PMID: 29183623      PMCID: PMC5750127          DOI: 10.1016/j.atherosclerosis.2017.08.031

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  35 in total

1.  Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase.

Authors:  Mitsuru Shimamura; Morihiro Matsuda; Hiroaki Yasumo; Mitsuyo Okazaki; Kazunori Fujimoto; Keita Kono; Tetsuya Shimizugawa; Yosuke Ando; Ryuta Koishi; Takafumi Kohama; Naohiko Sakai; Kazuaki Kotani; Ryutaro Komuro; Tatsuo Ishida; Kenichi Hirata; Shizuya Yamashita; Hidehiko Furukawa; Iichiro Shimomura
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-11-16       Impact factor: 8.311

Review 2.  Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?

Authors:  Ernst J Schaefer
Journal:  Curr Opin Lipidol       Date:  2013-06       Impact factor: 4.776

Review 3.  Endothelial lipase: a new lipase on the block.

Authors:  Sungshin Y Choi; Ken-ichi Hirata; Tatsuro Ishida; Thomas Quertermous; Allen D Cooper
Journal:  J Lipid Res       Date:  2002-11       Impact factor: 5.922

4.  Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.

Authors:  Mark J Graham; Richard G Lee; Teresa A Brandt; Li-Jung Tai; Wuxia Fu; Raechel Peralta; Rosie Yu; Eunju Hurh; Erika Paz; Bradley W McEvoy; Brenda F Baker; Nguyen C Pham; Andres Digenio; Steven G Hughes; Richard S Geary; Joseph L Witztum; Rosanne M Crooke; Sotirios Tsimikas
Journal:  N Engl J Med       Date:  2017-05-24       Impact factor: 91.245

5.  Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.

Authors:  Frederick E Dewey; Viktoria Gusarova; Richard L Dunbar; Colm O'Dushlaine; Claudia Schurmann; Omri Gottesman; Shane McCarthy; Cristopher V Van Hout; Shannon Bruse; Hayes M Dansky; Joseph B Leader; Michael F Murray; Marylyn D Ritchie; H Lester Kirchner; Lukas Habegger; Alex Lopez; John Penn; An Zhao; Weiping Shao; Neil Stahl; Andrew J Murphy; Sara Hamon; Aurelie Bouzelmat; Rick Zhang; Brad Shumel; Robert Pordy; Daniel Gipe; Gary A Herman; Wayne H H Sheu; I-Te Lee; Kae-Woei Liang; Xiuqing Guo; Jerome I Rotter; Yii-Der I Chen; William E Kraus; Svati H Shah; Scott Damrauer; Aeron Small; Daniel J Rader; Anders Berg Wulff; Børge G Nordestgaard; Anne Tybjærg-Hansen; Anita M van den Hoek; Hans M G Princen; David H Ledbetter; David J Carey; John D Overton; Jeffrey G Reid; William J Sasiela; Poulabi Banerjee; Alan R Shuldiner; Ingrid B Borecki; Tanya M Teslovich; George D Yancopoulos; Scott J Mellis; Jesper Gromada; Aris Baras
Journal:  N Engl J Med       Date:  2017-05-24       Impact factor: 91.245

6.  ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys.

Authors:  Viktoria Gusarova; Corey A Alexa; Yan Wang; Ashique Rafique; Jee Hae Kim; David Buckler; Ivory J Mintah; Lisa M Shihanian; Jonathan C Cohen; Helen H Hobbs; Yurong Xin; David M Valenzuela; Andrew J Murphy; George D Yancopoulos; Jesper Gromada
Journal:  J Lipid Res       Date:  2015-05-11       Impact factor: 5.922

7.  Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans.

Authors:  Stefano Romeo; Wu Yin; Julia Kozlitina; Len A Pennacchio; Eric Boerwinkle; Helen H Hobbs; Jonathan C Cohen
Journal:  J Clin Invest       Date:  2008-12-15       Impact factor: 14.808

Review 8.  Biochemistry and pathophysiology of intravascular and intracellular lipolysis.

Authors:  Stephen G Young; Rudolf Zechner
Journal:  Genes Dev       Date:  2013-03-01       Impact factor: 11.361

Review 9.  Impacts of angiopoietin-like proteins on lipoprotein metabolism and cardiovascular events.

Authors:  Takashi Miida; Satoshi Hirayama
Journal:  Curr Opin Lipidol       Date:  2010-02       Impact factor: 4.776

10.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics.

Authors:  Akin Akinc; Andreas Zumbuehl; Michael Goldberg; Elizaveta S Leshchiner; Valentina Busini; Naushad Hossain; Sergio A Bacallado; David N Nguyen; Jason Fuller; Rene Alvarez; Anna Borodovsky; Todd Borland; Rainer Constien; Antonin de Fougerolles; J Robert Dorkin; K Narayanannair Jayaprakash; Muthusamy Jayaraman; Matthias John; Victor Koteliansky; Muthiah Manoharan; Lubomir Nechev; June Qin; Timothy Racie; Denitza Raitcheva; Kallanthottathil G Rajeev; Dinah W Y Sah; Jürgen Soutschek; Ivanka Toudjarska; Hans-Peter Vornlocher; Tracy S Zimmermann; Robert Langer; Daniel G Anderson
Journal:  Nat Biotechnol       Date:  2008-04-27       Impact factor: 54.908

View more
  24 in total

1.  Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials.

Authors:  Safi U Khan; Muhammad U Khan; Shahul Valavoor; Muhammad Shahzeb Khan; Victor Okunrintemi; Mamas A Mamas; Thorsten M Leucker; Michael J Blaha; Erin D Michos
Journal:  Eur J Prev Cardiol       Date:  2019-09-02       Impact factor: 7.804

Review 2.  ANGPLT3 in cardio-metabolic disorders.

Authors:  Xin Su
Journal:  Mol Biol Rep       Date:  2021-03-06       Impact factor: 2.316

3.  Angiopoietin-like 4 promotes the intracellular cleavage of lipoprotein lipase by PCSK3/furin in adipocytes.

Authors:  Wieneke Dijk; Philip M M Ruppert; Lynette J Oost; Sander Kersten
Journal:  J Biol Chem       Date:  2018-07-18       Impact factor: 5.157

Review 4.  Therapeutic RNA-silencing oligonucleotides in metabolic diseases.

Authors:  Algera Goga; Markus Stoffel
Journal:  Nat Rev Drug Discov       Date:  2022-02-24       Impact factor: 84.694

5.  Metabolism of Triglyceride-Rich Lipoproteins.

Authors:  Jan Borén; Marja-Riitta Taskinen
Journal:  Handb Exp Pharmacol       Date:  2022

Review 6.  ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.

Authors:  Ioannis Akoumianakis; Evangelia Zvintzou; Kyriakos Kypreos; Theodosios D Filippatos
Journal:  Curr Atheroscler Rep       Date:  2021-03-10       Impact factor: 5.113

Review 7.  Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding.

Authors:  Allan D Sniderman; Patrick Couture; Seth S Martin; Jacqueline DeGraaf; Patrick R Lawler; William C Cromwell; John T Wilkins; George Thanassoulis
Journal:  J Lipid Res       Date:  2018-05-16       Impact factor: 5.922

Review 8.  Functional genomics and assays of regulatory activity detect mechanisms at loci for lipid traits and coronary artery disease.

Authors:  Tamara S Roman; Karen L Mohlke
Journal:  Curr Opin Genet Dev       Date:  2018-02-20       Impact factor: 5.578

9.  IL-10/STAT3 is reduced in childhood obesity with hypertriglyceridemia and is related to triglyceride level in diet-induced obese rats.

Authors:  Yuesheng Liu; Dong Xu; Chunyan Yin; Sisi Wang; Min Wang; Yanfeng Xiao
Journal:  BMC Endocr Disord       Date:  2018-06-13       Impact factor: 2.763

10.  EDEM3 Modulates Plasma Triglyceride Level through Its Regulation of LRP1 Expression.

Authors:  Yu-Xin Xu; Gina M Peloso; Taylor H Nagai; Taiji Mizoguchi; Amy Deik; Kevin Bullock; Honghuang Lin; Kiran Musunuru; Qiong Yang; Ramachandran S Vasan; Robert E Gerszten; Clary B Clish; Daniel Rader; Sekar Kathiresan
Journal:  iScience       Date:  2020-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.